Changeflow GovPing Pharma & Drug Safety Anti-SIRPalpha Antibody for Tumor Treatment
Routine Notice Added Final

Anti-SIRPalpha Antibody for Tumor Treatment

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

USPTO published patent application US20260098102A1 by National University Corporation Kobe University on April 9, 2026. The application discloses an anti-SIRPα monoclonal antibody that binds human SIRPα to inhibit the SIRPα/CD47 interaction for use as an anti-tumor agent. The invention is classified under C07K 16/28 and related peptide technology categories.

What changed

USPTO published patent application US20260098102A1 for National University Corporation Kobe University on April 9, 2026. The application discloses an anti-SIRPα antibody composition for tumor treatment, where the antibody specifically binds human SIRPα to inhibit SIRPα/CD47 checkpoint interaction.

Organizations engaged in immunooncology research or developing SIRPα/CD47-targeted therapeutics should review the patent claims for potential infringement concerns and assess licensing requirements. The assignee, filing date, and scope of claims provide relevant competitive intelligence for entities in the antibody therapeutics space.

What to do next

  1. Review patent claims for infringement analysis
  2. Conduct freedom-to-operate assessment
  3. Monitor for related patent filings

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

ANTI-SIRPalpha ANTIBODY

Application US20260098102A1 Kind: A1 Apr 09, 2026

Assignee

NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY

Inventors

Takashi MATOZAKI, Mayumi SUE, Kensuke NAKAMURA, Chigusa YOSHIMURA

Abstract

An anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47.

CPC Classifications

C07K 16/2896 A61K 2039/505 A61P 35/00 C07K 16/2863 C07K 16/2887 C07K 16/32 C07K 2317/21 C07K 2317/565 C07K 2317/72 C07K 2317/732 C07K 2317/76

Filing Date

2025-10-30

Application No.

19374973

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098102A1

Who this affects

Applies to
Educational institutions Investors Manufacturers
Industry sector
5417 Scientific Research
Activity scope
Patent application IP prosecution
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!